FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912686883> ?p ?o ?g. }

• W2912686883 endingPage "798" @default.
• W2912686883 startingPage "787" @default.
• W2912686883 abstract "Metastatic renal cell cancer (mRCC) patients have a median overall survival (mOS) of approximately 28 months. Until recently, mammalian target of rapamycin (mTOR) inhibition with everolimus was the standard second-line treatment regimen for mRCC patients, improving median progression-free survival (mPFS). Treatment with everolimus supports the expansion of immunosuppressive regulatory T cells (Tregs), which exert a negative effect on antitumor immune responses. In a phase 1 dose-escalation study, we have recently demonstrated that a low dose of 50 mg oral cyclophosphamide once daily can be safely combined with everolimus in mRCC patients and prevents the everolimus-induced increase in Tregs. In a multicenter phase 2 study, performed in patients with mRCC not amenable to or progressive on a vascular endothelial growth factor (VEGF)-receptor tyrosine kinase inhibitor (TKI) containing treatment regimen, we assessed whether the addition of this metronomic dosing schedule of cyclophosphamide to therapy with everolimus could result in an improvement of progression-free survival (PFS) after 4 months of treatment. Though results from this study confirmed that combination treatment effectively lowered circulating levels of Tregs, addition of cyclophosphamide did not improve the PFS rate at 4 months. For this reason, the study was abrogated at the predefined interim analysis. Although the comprehensive immunomonitoring analysis performed in this study provides relevant information for the design of future immunotherapeutic approaches, the addition of metronomic cyclophosphamide to mRCC patients receiving everolimus cannot be recommended." @default.
• W2912686883 created "2019-02-21" @default.
• W2912686883 creator A5004198017 @default.
• W2912686883 creator A5013858600 @default.
• W2912686883 creator A5014989295 @default.
• W2912686883 creator A5017136846 @default.
• W2912686883 creator A5022897881 @default.
• W2912686883 creator A5039412904 @default.
• W2912686883 creator A5047950538 @default.
• W2912686883 creator A5050495040 @default.
• W2912686883 creator A5051775146 @default.
• W2912686883 creator A5074784071 @default.
• W2912686883 creator A5084338724 @default.
• W2912686883 creator A5089910646 @default.
• W2912686883 date "2019-02-11" @default.
• W2912686883 modified "2023-10-01" @default.
• W2912686883 title "Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus" @default.
• W2912686883 cites W1543753614 @default.
• W2912686883 cites W1577123961 @default.
• W2912686883 cites W1832928186 @default.
• W2912686883 cites W1852876364 @default.
• W2912686883 cites W1941036222 @default.
• W2912686883 cites W1967200056 @default.
• W2912686883 cites W1973091654 @default.
• W2912686883 cites W2002198174 @default.
• W2912686883 cites W2013408555 @default.
• W2912686883 cites W2016398539 @default.
• W2912686883 cites W2017129287 @default.
• W2912686883 cites W2032700128 @default.
• W2912686883 cites W2035240798 @default.
• W2912686883 cites W2038723984 @default.
• W2912686883 cites W2039092335 @default.
• W2912686883 cites W2039754758 @default.
• W2912686883 cites W2054738595 @default.
• W2912686883 cites W2077699195 @default.
• W2912686883 cites W2078448383 @default.
• W2912686883 cites W2082830752 @default.
• W2912686883 cites W2084579140 @default.
• W2912686883 cites W2093350606 @default.
• W2912686883 cites W2099088585 @default.
• W2912686883 cites W2100669312 @default.
• W2912686883 cites W2102939102 @default.
• W2912686883 cites W2105459360 @default.
• W2912686883 cites W2110641805 @default.
• W2912686883 cites W2115005218 @default.
• W2912686883 cites W2116949558 @default.
• W2912686883 cites W2118677643 @default.
• W2912686883 cites W2121754497 @default.
• W2912686883 cites W2134131507 @default.
• W2912686883 cites W2138129102 @default.
• W2912686883 cites W2150594590 @default.
• W2912686883 cites W2153867442 @default.
• W2912686883 cites W2155012968 @default.
• W2912686883 cites W2156408558 @default.
• W2912686883 cites W2160476851 @default.
• W2912686883 cites W2162592936 @default.
• W2912686883 cites W2164317031 @default.
• W2912686883 cites W2222086386 @default.
• W2912686883 cites W2398103487 @default.
• W2912686883 cites W2521392361 @default.
• W2912686883 cites W2523992151 @default.
• W2912686883 cites W2572135803 @default.
• W2912686883 cites W2596504700 @default.
• W2912686883 cites W2726542547 @default.
• W2912686883 cites W2735520635 @default.
• W2912686883 cites W2763712070 @default.
• W2912686883 cites W2792937256 @default.
• W2912686883 cites W2900067554 @default.
• W2912686883 cites W2909448611 @default.
• W2912686883 doi "https://doi.org/10.1007/s00262-019-02313-z" @default.
• W2912686883 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30756132" @default.
• W2912686883 hasPublicationYear "2019" @default.
• W2912686883 type Work @default.
• W2912686883 sameAs 2912686883 @default.
• W2912686883 citedByCount "2" @default.
• W2912686883 countsByYear W29126868832020 @default.
• W2912686883 countsByYear W29126868832022 @default.
• W2912686883 crossrefType "journal-article" @default.
• W2912686883 hasAuthorship W2912686883A5004198017 @default.
• W2912686883 hasAuthorship W2912686883A5013858600 @default.
• W2912686883 hasAuthorship W2912686883A5014989295 @default.
• W2912686883 hasAuthorship W2912686883A5017136846 @default.
• W2912686883 hasAuthorship W2912686883A5022897881 @default.
• W2912686883 hasAuthorship W2912686883A5039412904 @default.
• W2912686883 hasAuthorship W2912686883A5047950538 @default.
• W2912686883 hasAuthorship W2912686883A5050495040 @default.
• W2912686883 hasAuthorship W2912686883A5051775146 @default.
• W2912686883 hasAuthorship W2912686883A5074784071 @default.
• W2912686883 hasAuthorship W2912686883A5084338724 @default.
• W2912686883 hasAuthorship W2912686883A5089910646 @default.
• W2912686883 hasBestOaLocation W29126868831 @default.
• W2912686883 hasConcept C126322002 @default.
• W2912686883 hasConcept C143998085 @default.
• W2912686883 hasConcept C190283241 @default.
• W2912686883 hasConcept C2776694085 @default.
• W2912686883 hasConcept C2776755627 @default.
• W2912686883 hasConcept C2777921159 @default.
• W2912686883 hasConcept C2779699572 @default.

• next